Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
NCT04438382 · ECOG-ACRIN Cancer Research Group · PHASE2 · terminated · last registry update 2026-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, ECOG-ACRIN Cancer Research Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-19Results posted on the registry: University of Washington, Apalutamide + Golimumab (NCT05960578)
- 2026-10-19Also stopped (terminated): University of Washington, Apalutamide + Golimumab (NCT05960578)
- 2026-07-23Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Golimumab (NCT05071664)
- 2026-06-22Also stopped (terminated): University Hospital, Montpellier, a drug against TNF (NCT03841942)
- 2026-06-03Results posted on the registry: Hawaii Pacific Health, Doxycycline + Placebo (NCT01917721)
- 2026-05-06Also stopped (terminated): Mats Remberger, Decidua Stroma Cells (DSC) + Best available Treatment (BAT) (NCT04118556)
- 2026-05-04Also stopped (suspended): Robert Flavell, MD, PhD, 89Zr-DFO-CZP (NCT03546335)
- 2026-03-11Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2026-03-11Also stopped (terminated): Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2025-12-26Also stopped (withdrawn): Therakos LLC, Methoxsalen + Infliximab (NCT06646016)
- 2025-12-02Results posted on the registry: The Leeds Teaching Hospitals NHS Trust, Methotrexate + Golimumab (NCT04108468)
- 2025-11-20Also stopped (terminated): Assistance Publique Hopitaux De Marseille, Methotrexate + Methotrexate Placebo (NCT02829424)
- 2025-11-14Results posted on the registry: Janssen Research & Development, LLC, Golimumab + Infliximab (NCT03596645)
- 2025-11-04Results posted on the registry: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2025-10-16Results posted on the registry: Janssen Research & Development, LLC, Placebo + Nipocalimab (NCT06028438)
- 2025-10-06Also stopped (withdrawn): Abu Dhabi Stem Cells Center, Anti-TNF + JAK inhibitor (NCT05379322)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision